RICHLAND, Wash., Sept. 26, 2017 /PRNewswire/ -- IsoRay, Inc.
(NYSE MKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced the acceptance for publication of a study
entitled "Re-irradiation using Permanent Interstitial Brachytherapy
(PIB): A Potentially Durable Technique for Salvaging Recurrent
Pelvic Malignancies" in the highly respected International Journal
of Radiation Oncology, Biology, Physics (the "Red Journal").
The accepted manuscript of the study was published on the Red
Journal's website on August 27, 2017.
The study was led by Jonathan
Feddock, M.D., Department of Radiation Medicine, Markey
Cancer Center, University of Kentucky,
Lexington, KY.
The study was conducted to evaluate whether re-irradiation using
permanent interstitial brachytherapy ("PIB") provides curative
potential to recurrent pelvic malignancies even in the setting of
prior radiation. Pelvic-only recurrent disease is challenging to
manage, with surgical removal of pelvic organs too often the only
option. This radical surgery carries with it a high rate of
complications and a large impact on a patient's quality of life.
PIB is an often forgotten, yet extremely useful local radiation
technique that can deliver targeted curative radiation doses, while
limiting the dose to uninvolved adjacent tissues. Cesium-131 is the
isotope of choice for PIB in gynecologic/pelvic cancers due to its
lower mean energy and lower toxicity profile compared to other
isotopes.
In the study forty-two patients were treated with 52 Cesium-131
implants. Median follow-up was 16.3 months. The study found that
women treated with PIB for small volume recurrences avoided radical
surgery and in most cases, toxicity was acceptable from the
re-irradiation. PIB also controlled local disease over a reasonably
long period of time, which contributed to preserving quality of
life. Importantly, even when PIB failed, the treatment was able to
provide the patients with a treatment option that provided improved
quality of life until time of recurrence – time that was free of a
colostomy or other significant morbidities.
Dr. Jonathan Feddock commented,
"Recurrent pelvic malignancies are difficult cancers to treat and
permanent interstitial brachytherapy using Cesium-131 has the
inherent ability to deliver curative radiation doses while limiting
the dose to uninvolved adjacent tissues. In addition, and perhaps
most importantly, the ability to avoid radical surgery and control
local disease is a major step forward for the quality of life of
these recurrent cancer patients."
"The durable positive outcomes achieved in Dr. Feddock's study
adds to the growing evidence of Cesium-131's efficacy in treating
multiple types of cancers," said Bill
Cavanagh, Chief Scientific Officer of IsoRay, Inc.
"Cesium-131's low toxicity profile and minimized impact on
patients' quality of life supports its promise to be effective for
many in need."
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay.
Follow us on Twitter@IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay, Inc.'s future
expectations, including the advantages of our products and their
delivery systems, whether Cesium-131 therapy will demonstrate
disease control in other recurrent pelvic malignancies or
cancers or will prove to be a safe approach compared to other
treatment options, the perception by the patient of quality of life
outcomes, , and all other statements in this release, other than
historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
("PSLRA"). This statement is included for the express purpose of
availing IsoRay, Inc. of the protections of the safe harbor
provisions of the PSLRA. It is important to note that actual
results could differ materially from those in such forward-looking
statements based on such factors as physician acceptance, training
and use of our products, our ability to successfully manufacture,
market and sell our products, our ability to manufacture our
products in sufficient quantities to meet demand within required
delivery time periods while meeting our quality control standards,
our ability to enforce our intellectual property rights, whether
additional studies are released that support the conclusions of
this and other past studies, whether ongoing patient quality of
life results with our products are favorable and in line with the
conclusions of clinical studies and initial patient results,
patient results achieved when our products are used for the
treatment of cancers and malignant diseases in conjunction with
other treatments, successful completion of future research and
development activities, whether we, our distributors, and our
customers will successfully obtain and maintain all required
regulatory approvals and licenses to market, sell, and use our
products in its various forms, continued compliance with ISO
standards, the success of our sales and marketing efforts, changes
in reimbursement rates, changes in laws and regulations applicable
to our products, and other risks detailed from time to time in
IsoRay, Inc.'s reports filed with the Securities and Exchange
Commission. Unless required to do so by law, IsoRay, Inc.
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/isoray-announces-study-accepted-for-publication-in-the-international-journal-of-radiation-oncology-biology-physics-entitled-re-irradiation-using-permanent-interstitial-brachytherapy-pib-a-potentially-durable-technique-for-sa-300525707.html
SOURCE IsoRay, Inc.